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A B S T R A C T
Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for
prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have
suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic
antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In
this review, we summarize the research efforts in vaccine development to date and the challenges faced in
achieving an efficient prophylactic or therapeutic vaccine against human CD.
1. Introduction
Chagas disease is a chronic degenerative illness inflicted by the
protozoan Trypanosoma cruzi. This infectious agent is prevalent in South
Central America and Mexico, and the disease is continually spreading
due to worldwide human migration efforts. An estimated 6–7 million
people, globally, are infected with T. cruzi and many more are exposed
to risk of infection. Routes of primary infection consist of direct trans-
mission by triatomine vector, consumption of food contaminated with
feces of infected triatomines, transfusion of blood from infected donors,
and vertical transmission from infected mothers to their newborns
(WHO: World Health Organization, 2019; Coura, 2015). Other routes of
transmission, e.g., transplantation of organs from infected individuals,
sexual transmission, laboratory accidents, are also described
(Coura, 2015). The oral route of transmission is noted to result in a
higher mortality rate of 8–35% than is generally observed by vector
transmission which is <5–10% (Antunes et al., 2019). T. cruzi infected
mothers can vertically transmit the parasite to the fetus in 5–10% of
pregnancies (Messenger and Bern, 2018). Benznidazole and nifurtimox
are the currently available chemotherapeutic treatment options
(Meymandi et al., 2018). These treatments were developed over 40
years ago and benznidazole is the only drug that is approved by US
Food and Drug Administration to treat T. cruzi infection (CDC, 2019).
These anti-parasitic drugs are most effective in treating the disease in
children and acutely infected adults. However, it is common for pa-
tients to suffer from unspecific symptoms, or be asymptomatic, leading
to lack of treatment. Patients will encounter a high parasitic load within
blood circulation during acute stage and a low to intermittent parasite
load during the chronic phase of the disease (D’Ávila et al., 2018).
Studies in mice infected with 105 trypomastigotes of T. cruzi (Y strain)
showed peak parasitemia developed by 5 days post infection (dpi) with
a median range of 9.3 × 104 parasite equivalent/mL (par. eq/mL); and
parasite levels fell below 10−1 par eq/mL at 100- and 260-dpi in in-
fected mice (Mateus et al., 2019). Acutely infected patients from Co-
lombia had median parasite loads of 6.68 par eq/mL (Hernández et al.,
2018). Chronic patients from Southern Brazil, tested for parasite load
via blood culture and analyzed using quantitative real-time PCR
(qPCR), had a median parasite load of 1.18 par eq/mL of blood
(D’Ávila et al., 2018). Another study of chronic patients from various
locations of Brazil determined a median load of 2.54 par eq/mL
(Rodrigues-dos-Santos et al., 2018). Chronic disease progression occurs
due to T. cruzi amastigote infiltration into organs, specifically cardiac
and digestive tissues. Approximately, 30–40% of chronically affected
Chagas patients will experience cardiomyopathies, and to a lesser ex-
tent, gastroenterological and neurologic disorders. Chagas disease can
ultimately cause death due to heart failure (Meymandi et al., 2018).
Although the immune system is required to control acute infection
(discussed below), low-grade systemic infection that persists during
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intermediate-to-chronic phase supports consistent activation of patho-
logic immune reactions and contribute to the pathogenesis of Chagas
heart disease (reviewed in (Marin-Neto et al., 2007; Gutierrez et al.,
2009; Rassi and Marin, 2017)). Indeed, with the advent of modern
techniques, e.g., PCR and qPCR, parasite DNA is detected in blood and
heart tissue biopsies of chronically infected animals and human patients
(D’Ávila et al., 2018; Gutierrez et al., 2009). Others have reported
transmission of T. cruzi via blood transfusion and transplantation of
infected organs obtained from asymptomatic individuals (Leiby et al.,
2000; Schmunis and Cruz, 2005; CDC, 2007; Angheben et al., 2015).
The reactivation of acute parasitemia in chronic individuals, following
immunosuppression after heart transplantation (Campos et al., 2008;
Gray et al., 2018), AIDS (Cordova et al., 2008; Lattes and Lasala, 2014)
or drug therapy (D’Almeida et al., 1996; Ribas et al., 2016), illustrates
that parasites persist for years after initial infection. It is, thus, accepted
by the research community that parasite persistence provides consistent
antigens that continue to trigger immune responses, cause pathologic
tissue injury leading to cardiac inflammation and fibrosis, and, subse-
quently, cardiac insufficiency (Fonseca et al., 2018).
Our work suggests that Chagas myocardium sustains oxidative stress
associated with mitochondrial dysfunction. A functional decline in the
respiratory chain and increased generation of reactive oxygen species
(ROS), coupled with an inability to efficiently scavenge mitochondrial
free radicals, predisposed the heart to oxidative insult during infection
and disease development (Garg, 2005; Zacks et al., 2005; Wen and
Garg, 2008; Wen and Garg, 2010; Lopez et al., 2018). The sustained
occurrence of oxidative adducts was shown in the myocardium of ex-
perimental models of Chagas disease (Wen et al., 2008; Wen et al.,
2004; Dhiman et al., 2012; Paiva et al., 2018) and in peripheral blood of
rodents and human Chagas subjects (Wen et al., 2006; de Oliveira et al.,
2007; Dhiman et al., 2008; Dhiman et al., 2009) that was exacerbated
by inefficient antioxidant capacity (Wen et al., 2004; Wen et al., 2006;
Wen et al., 2006; Perez-Fuentes et al., 2003; Wen et al., 2017;
Wan et al., 2016; Dhiman et al., 2013). Recent studies demonstrating
ROS signaling of cytokine and chemokine production in infected car-
diomyocytes and murine hearts (Gupta et al., 2009; Ba et al., 2010;
Wen et al., 2010; Barroso et al., 2016) have provided a potential me-
chanistic link between ROS generation and chronic inflammation in
Chagas cardiomyopathy.
Readers interested in further understanding the complexity of
Chagas pathogenesis for all stages of infection and disease are referred
to excellent recent reviews (Pinazo et al., 2015; Nunes et al., 2018).
2. Immunity to Trypanosoma cruzi infection
The innate immune system is the first to actively elicit a defensive
role followed by a cascade of components from the adaptive immune
response. Briefly, innate immunity is comprised of an anatomic barrier,
physiologic boundary, phagocytic cells and inflammatory components.
Skin and mucosal surfaces are anatomic barriers that prevent foreign
materials initial entry, while the complement system provides a phy-
siologic defense. Macrophages and neutrophils are the primary pha-
gocytic cells which consume pathogenic organisms. Dendritic cells are
also capable of phagocytosis and operate as antigen presenting cells
during an adaptive immune response. Basophils and mast cells are re-
sponsible for initiating an inflammatory response due to damage or
infection. Eosinophils have both inflammatory and phagocytic proper-
ties specific to the removal of parasites. Natural killer cells are im-
portant for the destruction of infected cells and provide the cytokine
interferon-gamma (IFN-γ). The adaptive immune response utilizes two
cell types: antigen specific T cells and B cells. Antigen presenting cells
signal the B cells differentiation into plasma cells that generate anti-
bodies. Dendritic cells, macrophages, and B cells are able to present
antigens to CD4+ and CD8+ T cells. CD8+ T cells directly destroy in-
fected cells, while CD4+ help amplify the immune response by re-
leasing cytokines. Cytokines and chemokines secreted by innate and
adaptive immune cells are responsible for cell recruitment, cell-to-cell
communication, and facilitating pathogen clearance by various me-
chanisms (Marshall et al., 2018).
T. cruzi interacts with different arms of the host immune defense in a
complex manner and is capable of establishing a persistent infection.
Recent reviews have discussed how parasite evades classical, lectin and
alternative complement pathways to establish infection (Acevedo et al.,
2018; Ferreira et al., 2014; Lidani et al., 2017). Studies in a variety of
experimental models showed that T. cruzi surface glycoproteins (mu-
cins) and/or glycophospholipids (GIPLs) are recognized by innate im-
mune cells and stimulate the production of multiple cytokines, e.g.,
IFN-γ, TNF-α, IL-1β, and IL-6; and chemokines, e.g., MCP-1, RANTES/
CCL5, and IP-10 (interferon gamma-induced protein 10) in macro-
phages (Almeida et al., 2000; Aliberti et al., 2001; Almeida and
Gazzinelli, 2001; Buscaglia et al., 2004; Fonseca et al., 2019). These
cytokines/chemokines induce macrophage production of superoxide
(O2•−) and nitric oxide (NO) that are important free radicals for direct
killing of T. cruzi (Martins et al., 1998). However, these free radicals are
produced at low levels, and not sufficient to clear the infection (Koo and
Garg, 2019). Others showed that IFN-γ promoted infection of astrocytes
by T. cruzi Colombian strain (Silva et al., 2015).
In mice acutely infected with T. cruzi Y strain, IFN-γ of NK origin
and IL-12 of macrophage origin supported the protective adaptive im-
munity constituted of parasite-specific type 1 T cells (Abrahamsohn and
Coffman, 1996). Parasite-specific CD4+ T cells assist in the control of T.
cruzi through secretion of Th1 cytokines (IFN-γ, IL-2), amplification of
phagocytic activity of macrophages, stimulation of B cell proliferation
and antibody production, and differentiation and activation of CD8+ T
cells (Brener and Gazzinelli, 1997). A strong lytic antibody response by
activated B cells enhances the opsonization, phagocytosis, and com-
plement-dependent killing of the parasites (Lidani et al., 2017;
Krautz et al., 2000). Yet, B cells also manage the inflammatory/anti-
inflammatory balance. Mice deficient in B cells responded to T. cruzi (Y
strain) with an increased frequency of TNF-α producing CD4+ T cells
and a decline in anti-inflammatory factors, including IL-10+, Fox3+,
and IL-17+ CD4+ T cells, which ultimately led to early death instigated
by toxic levels of inflammation (Gorosito Serrán et al., 2017). Humans
infected with T. cruzi display protection through antibodies that target
the parasites α-Gal epitope containing the Galα1,3-Galβ1,4-GlcNAc.
This epitope is present in a majority of the mucin glycoproteins ex-
pressed on the surface of T. cruzi trypomastigotes. Antibodies that
target the α-Gal epitope are expressed in high concentrations during
acute infection, detectable during chronic phase, and are capable of
killing the parasite independently of the presence of complement or
immune cells (dos Santos Virgilio et al., 2014). T. cruzi antigen-specific
CD8+ T cells are frequently present in infected mice and humans
(Wizel et al., 1997; Wizel et al., 1998), and suggested to contribute to T.
cruzi control through cytolysis of the infected cells and secretion of Th1
cytokines (IFN-γ) that induce trypanocidal activity (DosReis, 1997).
Some studies in chronically infected mice and patients suggest that
immune exhaustion of CD4+ and CD8+ T cells contribute to reduced
cytokine production and parasite persistence (Mateus et al., 2019;
Pérez-Antón et al., 2018). Conversely, others used mice chronically
infected with Brazil, TCC or Colombian strains of T. cruzi to show that
CD8+ T cells in infected organs were immunologically non-exhaustive;
and concluded that CD8+ T cell exhaustion was the unlikely culprit for
long-term parasite persistence (Pack et al., 2018). Other studies in-
dicate that too much of IFN-γ, IL-17, TNF-α cytokines correlates with
tissue damage and clinical disease in chronically infected patients
(Chevillard et al., 2018). Recent studies have also identified a role for
interleukin 27 (IL-27) in Chagas disease. IL-27, composed of epstein-
Barr virus-induced gene 3 (EBI3) and IL-27p28, is a member of the IL-
12 cytokine family, expressed by antigen presenting cells, and it in-
duces differentiation of diverse T cell populations and also upregulates
IL-10. In human Chagas patients, IL-27 expression was significantly
associated with cardiac protection. In mice chronically infected with T.
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cruzi Y strain, IL-27 regulated the proinflammatory IFN-γ and inhibited
cardiac muscle inflammation (Medina et al., 2017).
To sum up, these studies indicate that an efficient protective re-
sponse to T. cruzi infection requires elicitation of Th1 cytokines, lytic
antibodies, and the concerted activities of phagocytes, T helper cells,
and cytotoxic T lymphocytes; and an absence of either of these com-
ponents can result in parasite persistence associated pathologic events
contributing to cardiomyopathy and heart failure in the host.
3. Vaccine development against T. cruzi and Chagas disease
Given the detailed knowledge about the status of anti-T. cruzi pro-
tective immunity discussed above, a successful vaccine against the
parasite is envisioned to elicit lytic antibody response, type 1 cytokines,
and cytotoxic T lymphocytes (dos Santos Virgilio et al., 2014;
Gupta et al., 2019). It is generally accepted by the research community
that a vaccine should include antigens targeting all stages of the para-
site and should be useful as a prophylactic and therapeutic vaccine
(Dumonteil et al., 2019; Bustos et al., 2019; Quijano-Hernandez and
Dumonteil, 2011). Computational modeling studies show that a vaccine
against T. cruzi would be economically viable and provide net cost
savings, even with stringent simulation parameters of 1% infection risk,
treatment efficacy of 25%, and a cost of $20/dose (Lee et al., 2010;
Lee et al., 2012). With an efficacy of >50% and infection risk of 20%,
vaccine costing even >$200 would also be economically advantageous
(Lee et al., 2010; Lee et al., 2013). A safe, effective, and reliable vaccine
will also alleviate the costs for vector control and drugs used to dispel
this infection in endemic countries (Ma et al., 2015).
3.1. Live and attenuated whole organism vaccines
The proponents of the live and attenuated vaccine believe that such
a vaccine will provide a full spectrum of antigenic epitopes for stimu-
lation of protective immunological responses. Early efforts utilized
whole parasites killed by chemical, physical or irradiation methods or
sub-cellular fractions (e.g., flagellar, soluble, or parasite membrane
fractions) for their prophylactic vaccine potential in various animal
models, including mice, guinea pigs, dogs, and monkeys. While che-
mically treated T. cruzi provided no protection from lethal challenge
infection, other approaches generated a degree of resistance to T. cruzi
and a large percentage of immunized animals survived from acute in-
fection (reviewed in Bhatia et al., 2009; Vazquez-Chagoyan et al., 2011;
Rodriguez-Morales et al., 2015). Live vaccines, constituted of T. cruzi
strains attenuated by treatment with pharmacological agents or by se-
rial passage in cultures have also been tested for their potency in ex-
perimental animals (reviewed in Sanchez-Valdez et al., 2015). With the
advancement of CRISPR and other technologies to knockdown genes in
trypanosomes, recent efforts have also focused on utilizing the geneti-
cally modified T. cruzi knocked down in one or more virulence genes as
live vaccines. These live vaccines were largely effective in controlling
challenge infection; vaccinated animals exhibited decreased para-
sitemia and increased survival rates compared to the unimmunized
animals (Quijano-Hernandez and Dumonteil, 2011). Further efforts will
determine if a live vaccine protective against one lineage of T. cruzi
would be efficacious in providing protection against infection from the
other five lineages of T. cruzi. Some researchers also remain concerned
that an attenuated live vaccine may trigger a full-blown infection and
disease in immunocompromised individuals (Sanchez-Valdez et al.,
2015).
Phytomonas serpens, a tomato parasite that shares antigens with T.
cruzi but is non-pathogenic to humans, has also been used as a potential
prophylactic vaccine. Authors noted that mice immunized with P. ser-
pens followed by challenge infection with lethal dose of T. cruzi Y strain
(5 × 103 or 105 trypomastigotes) exhibited a significant decrease in
parasitemia and mortality (Bregano et al., 2003). Basso and colleagues
have promoted the use of Trypanosoma rangeli, which shares significant
sequence homology with T. cruzi and infects triatomines and mammals
but does not cause disease in humans, as a prophylactic vaccine
(Basso and Marini, 2015). Indeed, mice immunized with glutar-
aldehyde-fixed T. rangeli epimastigotes were protected from challenge
infection with a virulent isolate (Tulahuen) of T. cruzi (102 trypomas-
tigote inoculum) (Introini et al., 1998). In our studies, we found that
glutaraldehyde fixed T. rangeli itself did not offer protection from
challenge infection in mice and dogs. Including fixed T. rangeli with a
subunit DNA vaccine consisting TcG2 and TcG4 did not enhance the
vaccine's efficacy in mice (Gupta et al., 2019). However, DNA vaccine
(consisting TcG1, TcG2 and TcG4 subunits) adjuvanted with fixed T.
rangeli provided significant protection against Sylvio X10/4 strain of T.
cruzi that is highly pathogenic in dogs (Aparicio-Burgos et al., 2015).
Overall, we believe that the concerns in the use of T. rangeli or T.
cruzi based attenuated vaccines appear to outweigh the benefits offered
by whole organism vaccine in the context of Chagas disease.
3.2. Selection of T. cruzi antigens for subunit vaccines
Early studies utilized T. cruzi cDNA expression libraries and per-
formed immune screening with sera from infected animals or human
patients to detect the antigenic candidates (referenced below). This
approach identified the candidates that were recognized by anti-para-
site antibodies but may or may not consist of epitopes for T cell acti-
vation. Subsequently, Garg et al. (1997) utilized recombinant T. cruzi
expressing a model antigen (chicken ovalbumin) in different cellular
compartments to demonstrate that parasite GPI- anchored proteins
(glycosylphosphatidylinositol), that are abundantly expressed in in-
fective and intracellular stages of T. cruzi and released in host cell cy-
toplasm during parasite differentiation, are the most likely source of
peptides for immune activation of B and T cells. Accordingly, several
surface proteins of T. cruzi that belong to the abundantly expressed
surface antigens of the large families, e.g., trans-sialidase (TS) super
family (737 genes), mucins (662 genes), mucin-associated surface
proteins (MASPs, 944 genes), and glycoprotein 63s (GP63s, 174 genes)
(El-Sayed et al., 2005) have been selected as vaccine candidates. For
example, among the members of the TS superfamily, trypomastigote
surface antigen (TSA1, 85 kDa), TS, and amastigote surface proteins
(ASP1, ASP2, ASP9 (ASP-2 like clone 9)) were shown to be recognized
by antibody response and CD8+ T lymphocytes in infected mice and
humans (Wizel et al., 1997; Wizel et al., 1998; Low and Tarleton, 1997;
Pereira-Chioccola et al., 1994; Ribeirao et al., 2000; Santos et al., 1997;
Boscardin et al., 2003; Low et al., 1998). Mucins contain a large pro-
portion (85%) of O-glycosidic-linked carbohydrates (Schenkman et al.,
1993), and GPI component of GP35/50, SSP3 and other mucins was
noted to be a powerful inducer of polyclonal B cells, inflammatory
cytokines and macrophages (Bhatia et al., 2009; Acosta-Serrano et al.,
2001; Cardoso et al., 2013; de Paulo Martins et al., 2010). Other anti-
gens that do not belong to large families, but nevertheless were tested
for their antigenic potential include complement regulatory protein
(CRP or gp160) (Norris et al., 1994), a lysosomal cysteine proteinase
(cruzipain, 60 kDa) (Fonseca et al., 2005), flagellar calcium binding
protein (FCaBP or Tc24, 24 kDa) (Godsel and Engman, 1999, Krautz
et al., 1998), GP90 (90 kDa) and GP82 (82 kDa) (Yoshida et al., 1993),
kinetoplastid membrane protein (KMP-11, 11 kDa) (Trujillo et al.,
1999; Maranon et al., 2001), LYT1 (61 kDa) (Fralish and
Tarleton, 2003), paraflagellar rod proteins (70–86 kDa)
(Wrightsman et al., 2002; Michailowsky et al., 2003), and TC52 (52
kDa) (Fernandez-Gomez et al., 1998). These antigens were shown to be
recognized by antibodies and IFN-γ-producing CD8+ T cells in experi-
mental models of T. cruzi infection and/or Chagas subjects. These T.
cruzi surface membrane proteins are discussed in recent reviews (Pech-
Canul et al., 2017; De Pablos and Osuna, 2012).
We have employed a computational algorithm to screen the T. cruzi
sequence database for desirable B and T epitopes (Bhatia et al., 2004;
Bhatia and Garg, 2008), and then performed a biological screen to
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identify those that were recognized by IgGs and elicited type 1 CD8+T
cell response in infected mice, dogs, and humans (Bhatia et al., 2004;
Bhatia and Garg, 2008; Gupta et al., 2013; Aparicio-Burgos et al., 2011;
Bhatia et al., 2004; Garg and Bhatia, 2005). Of the 11 antigens thus
selected, TcG1, TcG2, and TcG4 passed additional criteria for vaccine
design. The three candidate antigens were (a) expressed (mRNA/pro-
tein) in mammalian stages of T. cruzi (Bhatia et al., 2004; Bhatia and
Garg, 2008), (b) released in host cell cytoplasm during parasite differ-
entiation (Bhatia et al., 2004; Bhatia and Garg, 2008), and (c) consisted
of epitopes presented by MHC alleles of mice, dogs (Aparicio-
Burgos et al., 2015; Aparicio-Burgos et al., 2011), and humans
(Gupta et al., 2013). Notably, TcG2 and TcG4 were conserved in five of
the six T. cruzi lineages (80–96% homology), providing confidence that
TcG2/TcG4-based vaccine would provide protection against diverse Tc
isolates in the US and Latin America (Gupta et al., 2019; Bhatia et al.,
2004). Immune properties of some of the antigenic targets selected for
vaccine efficacy studies are listed in Table 1.
3.3. Subunit vaccines
Several investigators have utilized a protein immunization approach
to test the vaccine potential of T. cruzi antigens (Wizel et al., 1997;
Low et al., 1998; Serna et al., 2014). Others favored the DNA im-
munization approach due to the ease of construction and production of
the vectors, the stability of DNA and the ability to enhance the immune
response by the co-delivery of genes encoding cytokines (Gupta et al.,
2019; Bhatia and Garg, 2008; Aparicio-Burgos et al., 2011;
Vasconcelos et al., 2003). Most importantly, antigen delivery by DNA
vaccination has proved to be efficient in eliciting antibodies, Th1 cy-
tokines and CD8+ T cell immune responses to encoded antigens
(Aparicio-Burgos et al., 2011; Gupta and Garg, 2015). Efforts were also
made to enhance the protective efficacy of recombinant protein and
DNA vaccines by use of alternative routes of antigen delivery, by
increasing the amount or the number of doses, and heterologous prime-
boost strategies (Gupta and Garg, 2015). In parallel with the efforts
towards testing of vaccine candidates, adjuvants were tested to enhance
or skew the immune responses toward desirable Th1 type. Accordingly,
studies have examined the utility of IL-12, GM-CSF, CD40, HSP70, and
CpG oligodeoxynucleotides (ODN-CpG), among others, in enhancing
the Th1 responses to defined antigen vaccines (Corral and
Petray, 2000). Several reviews have discussed the vaccine potential of
antigenic candidates in experimental models (Vazquez-Chagoyan et al.,
2011; Rodriguez-Morales et al., 2015; Arce-Fonseca et al., 2015).
Herein, we discuss in brief the past literature and add the updates as
relevant.
A majority of studies have tested the efficacy of genes/proteins as
prophylactic vaccine in murine models (summarized in Table 2). A few
studies that have tested the therapeutic immunization are discussed
where relevant, and also mentioned in Table 2. Some investigators
tested immunization with a single gene/protein, and others have uti-
lized multi-component candidate vaccines. The ability of the individual
or mixed genes to elicit protection from challenge infection depended
upon the amount of the given recombinant protein or antigen-encoding
plasmid sufficient to elicit protective B and T cell responses. For ex-
ample, we have tested various dilutions of ASP1, ASP2, and TSA1
(0.001-33 µg/mouse), and showed that the level of resistance to T. cruzi
infection correlated with the amount of DNA delivered, the maximal
protection being obtained with 1 µg (or higher) amount of each can-
didate with IL-12 and GM-CSF cytokine adjuvants (Garg and
Tarleton, 1998). Yet, the level of protection from T. cruzi infection in-
duced in mice immunized with these antigens (individually or in
combination) (Fralish and Tarleton, 2003, Garg and Tarleton, 2002)
was not sufficient to offer sterile immunity and no protection was ob-
served in mice immunized with a pool of genes encoding mucin family
members (Fralish and Tarleton, 2003). Researchers postulated that
genes of large families express shared epitopes that when delivered
Table 1
Properties of some of the T. cruzi antigenic targets.
Antigen Model Recognition by immune
components
References
TSA-1 C57BL/6 mice, Human
(PBMC's)
MHC-I, CD8+ T cell, HLA-A2 Wizel et al. (1997), Wizel et al. (1998)
ASP1 C57BL/6, C3H/HeSnJ mice,
Human (PBMC's)
MHC-I, CD8+ T cell, HLA-A2 Wizel et al. (1998), Santos et al. (1997), Low et al. (1998)
ASP2 (ASP-2-like clone 9) BALB/c, C3H/HeJ, C57BL/6
mice, Human (PBMC's)
CD4+ Th1, CD8+ CTL, HLA-A2 Wizel et al. (1998), Boscardin et al. (2003), Barbosa et al. (2013),
Ribeiro et al. (2019), Pereira et al. (2015)
MASP BALB/c mice, Human (sera) B cells, CD8+ T cell, IgM,
IgG2A, IgA
Serna et al. (2014), Durante et al. (2017)
Tc24 (FCaBP) BALB/c, ICR mice Th1, IgG2b Krautz et al. (1998), Sanchez-Burgos et al. (2007), Dumonteil et al. (2004),
Taibi et al. (1993), Martinez-Campos et al. (2015)
TSA-1 & Tc24 Human (PBMC's) HLA-A, HLA-B Villanueva-Lizama et al. (2018)




Norris et al. (1994), Sepulveda et al. (2000)
Cruzipain Human (PBMC's) HLA-A2, CD8+ T cell Fonseca et al. (2005)
Cruzipain BALB/c mice Th2, CD19+ Guiñazú et al. (2004)
Cruzipain C57BL/6 mice Th1, CD4+ TGFβ+ Guiñazú et al. (2004)
TcG1, TcG2, & TcG4 C57BL/6 mice Th1, IgG2b/ IgG1 Bhatia and Garg (2008)
Gp63 NA NA Cuevas et al. (2003)
Gp35/50 BALB/c mice anti-sera No response Yoshida et al. (1993)
Gp82 & gp90 BALB/c mice anti-sera Complement mediated lysis,
CD4+ T cell
Yoshida et al. (1993)
Ssp3 NA NA Frevert et al. (1992)
KMP-11 Human (sera) IgG1, IgG3, IgG4 Flechas et al. (2009)
LYT1 C57BL/6 mice CD8+ CTL Fralish and Tarleton (2003)
PFR1, PFR2 C57BL/6, BALB/c mice CD8+ CTL Wrightsman et al. (2002)
PFR2 or PFR3 BALB/c mice, Human (PBMC's) CD8+ CTL, HLA-A Egui et al. (2012)
Tc52 ICR mice NA Sanchez-Burgos et al. (2007)
Abbreviations: ASP2 - amastigote surface protein 2; CRP - complement regulatory protein; CTL - cytotoxic T lymphocyte; HLA - human leukocyte antigen (type A and
type B); Ig - immunoglobulin isotypes; MASP – mucin-associated surface protein; MHC-1 - major histocompatibility complex 1; PBMCs - peripheral blood mono-
nuclear cells; Tc24 - trypomastigote excretory–secretory protein 24; TSA - trypomastigote surface antigen; Th1 - T helper type 1; Ssp3 - stage-specific antigen 3; KMP -
kinetoplastid membrane protein; PFR (1, 2 or 3) - paraflagellar rod protein (1, 2 or 3); NA - not available.
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together may not offer additive protective benefits in in-bred mice. Yet,
it was predicted that the potential synergistic immunologic benefit of a
combination of epitopes from many genes would stimulate a larger
frequency of immune effectors in heterogeneous host populations and
provide efficient immunity against diverse parasite strains (Vazquez-
Chagoyan et al., 2011), to be verified in future studies.
Other investigators have tested the vaccine efficacy of non-family
proteins in a variety of in-bred mouse models. For example, Cazorla
et al. used a Salmonella carrying Cz-DNA (SCz) and adjuvants (CpG-
ODN, GM-CSF, MALP-2) in mice. SCz oral doses induced a mucosal
immune response (IgA) but weak systemic immune response, while
including a boost with recombinant CZ protein and CpG-ODN produced
a strong systemic immune response (i.e., antigen-specific IgG, splenic
lymphocyte proliferation and IFN-γ production) that provided sig-
nificant protection from challenge infection and tissue damage
(Cazorla et al., 2008).
Immunization of mice with PFR2 and PFR3 genes (encode for par-
aflagellar rod proteins) alone or fused to the 70 kilodalton heat shock
protein (HSP70) induced high levels of anti-PFRs IgG2a; however, only
the PFR2-HSP70 immunization induced a significant increase in the IL-
12 and IFN-γ expression and a degree of protection against T. cruzi
experimental infection (Egui et al., 2012; Morell et al., 2006).
Recently, prophylactic vaccine efficacy of α-Gal epitope,
Galα13Galβ14GlcNAc bound to human serum albumin (HSA) was in-
vestigated. C57BL/6 mice immunized with this vaccine elicited anti-α-
Gal antibody-mediated humoral reaction and were protected from le-
thal challenge infection with T. cruzi Y strain (1 × 105 parasite in-
oculum). Authors also observed a decline in parasite burden, T cell
permeation in tissues, necrotic myocytes and cardiac inflammation in
the heart of vaccinated (vs. non-vaccinated) mice (Portillo et al., 2019).
Screening of a cDNA expression library with anti-amastigote
monoclonal antibodies identified FCaBP (Tc24), Tcb3 and LYT1 genes
as potential antigens for vaccine design. The three gene peptides in-
duced a response of cytotoxic T cells in chronically infected mice;
however, the immunization with only LYT1 gene protected 80% of mice
from T. cruzi lethal challenge (Fralish and Tarleton, 2003), thus, sug-
gesting that proteins that may be recognized by immune responses in an
infected host may not always be the best candidates for vaccine de-
velopment.
Other groups used recombinant adenovirus serotype 5 as vector and
evaluated the protection raised by immunization of mice (C57BL/6 and
C3H/HeJ) with recombinant Ad5 encoding amastigote surface protein
2 (ASP2). This immunization protocol elicited a robust expansion of
CD8+ effector T cells producing TNF-α, IFN-γ, and a higher mobiliza-
tion of surface marker CD107a that is indicative of cytolytic activity
and provided significant protection against challenge infection with T.
cruzi Y strain (Barbosa et al., 2013). Afterwards, the therapeutic effects
were evaluated in mice simultaneously infected with T. cruzi (Y strain)
and immunized by AdASP-2. A significant control of tissue amastigote
nests associated with a rapid immune response characterized by the
expression of inflammatory genes, such as iNOS, TNF-α, TLR-4, and IL-
10 was noted in mice therapeutically vaccinated with Ad-ASP2
(Ribeiro et al., 2019). Pereira et al. (2015) also used recombinant Ad5
encoding ASP2 and TS sequences and tested their prophylactic and
therapeutic efficacy in C57BL/6 mice that were acutely or chronically
infected with T. cruzi Colombian strain. These authors found there was
an increase in CD8+ T cells and production of IFN-γ, accompanied by a
decrease in cardiac electrical alterations and cardiac tissue parasite
burden in mice given prophylactic vaccine. Therapeutic treatment of
chronic mice with Ad5-ASP2 / Ad5-TS enhanced survival, reduced
electrocardiogram abnormalities, maintained IFN-γ concentrations, and
decreased CD107a+ CD8+ T cells and plasma nitric oxide production
(Pereira et al., 2015). Taken together, these results suggest promising
application of ASP2-expressing recombinant virus as a prophylactic and
therapeutic vaccine against acute and chronic infection.
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oligopeptidase (Tc80) as a novel immunogen for Chagas vaccine.
Authors immunized mice with recombinant Tc80 protein and re-
combinant Salmonella encoding Tc80 (STc80) in a prime-boost ap-
proach, and showed that immunized mice elicited Tc80-specific, com-
plement-dependent trypanolytic antibodies, splenic production of Th1
cytokines, such as IFN-γ, IL-2 and TNF-α, as well as polyfunctional
CD4+ T cells and cytotoxic T lymphocytes associated with significant
protection from challenge infection and chronic pathology
(Bivona et al., 2018).
We have followed the protective efficacy of three antigens TcG1,
TcG2, TcG4 in two experimental models (mice and dogs). Studies in
mice were conducted with delivery of the three antigens (individually
or in combination) by several prime / boost approaches (e.g., DNA/
DNA, DNA/protein, or DNA/ Modified Vaccinia Ankara (MVA)). In all
cases, we showed that vaccine provided 80-90% protection from acute
parasite burden and chronic myocarditis in mice (Bhatia et al., 2004;
Bhatia and Garg, 2008; Gupta and Garg, 2010). The overall extent of
protection was associated with elicitation of trypanolytic antibodies,
Th1 cytokine response, and CD8+ T cells cytolytic activity. In further
studies, we also found that TcG1 is dispensable, and TcG2/TcG4-based
two component candidate vaccine was highly effective (Gupta and
Garg, 2015). Importantly, these studies showed an increase in in-
flammatory responses in the vaccinated mice immediately after chal-
lenge infection; however, chronic inflammatory infiltrate was de-
creased in the vaccinated mice. Each of the delivery modes had several
advantages and drawbacks. For example, DNA vaccine was the simplest
in design, and delivery of DNA vaccine via intradermal/electroporation
route (vs. intramuscular route) was most effective in generating pro-
tective immunity to challenge infection (Hegazy-Hassan et al., 2019).
Further, Hegazy-Hassan et al found that the use of a single intradermal
electroporation dose of 10 µg of TcG2 and TcG4 DNA vaccine without
adjuvants, induced a protective immune response reducing the amount
of DNA and eliminating the need for boost immunizations. DNA-protein
vaccine was very complex-requiring two doses of six DNA-encoding
plasmids and two doses of three recombinant proteins (Gupta and
Garg, 2015). In contrast, MVA can accommodate multiple foreign genes
in its genome, can be administered by a variety of routes, has an ex-
cellent safety record, and was shown to generate immune responses to a
variety of foreign antigens (Meseda et al., 2002). MVA itself can act as
an adjuvant to signal the innate immune system and boost T cells
(Climent et al., 2011).
As in mice, dogs immunized with TcG1, TcG2, and TcG4- based
vaccine also showed significant protection from challenge infection and
acute myocarditis (Bhatia et al., 2004; Bhatia and Garg, 2008; Aparicio-
Burgos et al., 2011). Others have shown the TcSP and TcSSP4 encoding
DNA vaccine induced anti-parasite IgG2 and IFN-γ-producing lympho-
cytic cell proliferation in dogs. Upon challenge infection, TcSP- and
TcSSP4-immuninzed dogs exhibited a moderate control of tissue para-
sites and electrocardiographic aberrations (Arce-Fonseca et al., 2013).
3.4. Therapeutic vaccines against Chagas disease
The overall basis for therapeutic vaccines is to modulate or enhance
the multiple effector mechanisms against T. cruzi so as to clear the
parasite's persistence in the infected host. Several candidate antigens
(e.g. TSA-1, TS, Tc52, Tc24 and ASP-2) all belonging to trans-sialidase
family, have been tested for therapeutic efficacy in acutely or chroni-
cally infected mice. When tested in mice immediately after infection or
within two weeks post-infection, Tc52, TSA-1 and Tc24 DNA vaccine
decreased the parasitemia and mortality from infection (Sanchez-
Burgos et al., 2007; Dumonteil et al., 2004) that was associated with a
vaccine- induced rapid increase in the number of CD4+ and CD8+ T
cells (Zapata-Estrella et al., 2006). However these same candidates did
not arrest cardiomyopathy in chronically infected mice or infected dogs
(reviewed in Quijano-Hernandez et al., 2008). Others showed that
therapeutic delivery of ASP2 and TS (individually or in combination as
DNA vaccine) did not limit parasitemia or improve the survival rate in
infected mice (Sanchez-Burgos et al., 2007; Dumonteil, 2007) despite
the fact that these antigens have exhibited excellent efficacy as a pro-
phylactic vaccine. Some studies also observed an increase in myo-
carditis in infected mice inoculated with TSA1 DNA vaccine (Zapata-
Estrella et al., 2006).
In a recent study, Barry et al. (2016) have explored the potential for
a nanoparticle, therapeutic vaccine. Authors encapsulated Tc24 protein
in poly(lactic-co-glycolic acid) nanoparticle and used the nanoparticles
to immunize mice that were previously infected with a highly lethal T.
cruzi H1 strain (5 × 104 trypomastigotes inoculum). Mice immunized
with Tc24 nanoparticles exhibited a Th1 immune response with an
increase in splenic antigen-specific IFN-γ, IgG2A, and CD8+ T cells.
There was also a visible reduction in inflammatory cell infiltrate and
parasite load in tissues (Barry et al., 2016). In another study, the same
group utilized Tc24 recombinant protein along with E6020 adjuvant to
immunize mice chronically infected with T. cruzi H1 strain (500 try-
pomastigotes inoculum) and showed that 60% of therapeutically vac-
cinated mice had untraceable parasitic levels, accompanied with a de-
crease in cardiac fibrosis (Barry et al., 2019).
In our experience, a therapeutic approach focused on the control of
the parasite burden is not sufficient to arrest the progression of chronic
disease, and immune therapy against parasite persistence should be
adjuvanted with other agents to prevent cardiac damage. It is shown
that repeat challenge infection of mice enhanced the immune responses
but did not provide protection from parasite persistence and cardiac
damage in chronically infected mice (Rosas-Jorquera et al., 2013). We
noted that infected mice and rats, treated with chemotherapeutic drug
(benznidazole) during the indeterminate phase-controlled parasite
persistence; however, failed to avert cardiac remodeling and dete-
rioration of ventricular contractility. Instead, maximal benefits were
obtained when infected mice and rats were treated with benznidazole,
in conjunction with PBN (phenyl-alpha-tert-butyl nitrone) antioxidant
to prevent free radical-mediated oxidative insult and mitochondrial
deficiencies. This resulted in the preservation of oxidative phosphor-
ylation and left ventricular contractile activity in Chagas hearts
(Wen et al., 2010). Likewise, we noted a better efficacy of a TG2/TcG4-
based therapeutic vaccine in infected mice that overexpressed glu-
tathione peroxidase and were capable of controlling the oxidative da-
mage caused by mitochondrial deficiencies of electron transport chain
of antioxidant response (Gupta et al., 2015). In comparison, wild type
infected mice continued to mount cardiac damage after TG2/TcG4
therapeutic vaccine (Gupta et al., 2015). We, therefore, propose that
therapeutic vaccines designed to achieve a rapid, short-lived stimula-
tion of type 1 cellular immunity to attack persistent parasites, but
prevent cellular injury, along with adjunct therapies capable of con-
trolling the onset of oxidative insult and mitochondrial deficiencies,
would prove to be maximally beneficial in preserving cardiac structure
and function in Chagas disease.
4. Summary and future directions
An immune therapy that will control the T. cruzi transmission and
chronic Chagas cardiomyopathy is urgently needed. In last few decades,
significant research efforts have led to the development of several ex-
perimental vaccines that have shown promising results in small animal
models of T. cruzi infection and Chagas disease. We call for significant
level of academic-public-private partnership to support future scientists
who will test the current and new vaccines against T. cruzi in large
animal models and seek further development of the best possible im-
mune therapy to prevent human Chagas cardiomyopathy.
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